title: Effects of beta-hydroxy-beta-methylbutyrate on muscle damage after a prolonged run.
abstract: This study examined the effects of supplemental beta-hydroxy-beta-methylbutyrate (HMB) on muscle damage as a result of intense endurance exercise. Subjects (n = 13) were paired according to their 2-mile run times and past running experience. Each pair was randomly assigned a treatment of either HMB (3 g/day) or a placebo. After 6 wk of daily training and supplementation, all subjects participated in a prolonged run (20-km course). Creatine phosphokinase and lactate dehydrogenase (LDH) activities were measured before and after a prolonged run to assess muscle damage. The placebo-supplemented group exhibited a significantly greater (treatment main effect, P = 0.05) increase in creatine phosphokinase activity after a prolonged run than did the HMB-supplemented group. In addition, LDH activity was significantly lower (treatment main effect, P = 0.003) with HMB supplementation compared with the placebo-supplemented group. In conclusion, supplementation with 3.0 g of HMB results in a decreased creatine phosphokinase and LDH response after a prolonged run. These findings support the hypothesis that HMB supplementation helps prevent exercise-induced muscle damage.
authors.affiliation: Human Performance Laboratory, Iowa State University, Ames, Iowa 50011, USA.
authors.forename: A E
authors.initials: AE
authors.lastname: Knitter
authors.forename: L
authors.initials: L
authors.lastname: Panton
authors.forename: J A
authors.initials: JA
authors.lastname: Rathmacher
authors.forename: A
authors.initials: A
authors.lastname: Petersen
authors.forename: R
authors.initials: R
authors.lastname: Sharp
mesh_terms: D000328:Adult; D001823:Body Composition; D003402:Creatine Kinase / Q000097:blood; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D010101:Oxygen Consumption / Q000187:drug effects*; D010919:Placebos; D012420:Running / Q000502:physiology*; D014631:Valerates / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
chemical_list: D010919:Placebos; D014631:Valerates; C004961:beta-hydroxyisovaleric acid; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase